相关实验视频
Updated: Jun 25, 2025

16:24
Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells
Published on: February 21, 2014
20.2K
阐明微RNA-18a在推进混合上皮层-半细胞表型和驱动ER阴性乳腺癌恶性进展中的作用
Madhumathy G Nair1, Apoorva D Mavatkar1, Chandrakala M Naidu1
1Division of Molecular Medicine, St. John's Research Institute, St. John's Medical College, Bangalore 560034, Karnataka, India.
Cells
|May 24, 2024
概括
低的miR-18a表达在ER阴性乳腺癌中驱动了像迁移和茎状的侵略性特征. 这项微RNA (miRNA) 研究揭示了亚型在瘤进展和转移中的特定作用.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
背景情况:
- 表观遗传变化,包括microRNA (miRNA) 变化,影响瘤细胞状态,表皮-介质细胞过渡 (EMT) 和乳腺癌转移.
- 侵袭性ER阴性亚型在理解瘤进展方面提出了独特的挑战.
研究的目的:
- 调查微RNA-18a (miR-18a) 在调解ER阴性乳腺癌中混合上皮/介质细胞 (E/M) 细胞状态中的作用.
- 评估miR-18a表达在乳腺癌进展中的临床相关性和功能影响.
主要方法:
- 分析患者获得的乳腺瘤样本 (n=446) 和公共基因表达数据集中的miR-18a表达.
- 在体外和体内乳腺癌模型中的验证.
- 对miR-18a目标和相关信号通路的生物信息分析,包括缺氧诱导因子1-alpha (HIF-1α).
主要成果:
- 在ER阴性瘤中下调的miR-18a表达与混合E/M细胞的丰富相关.
- 这些细胞表现出光的属性,增强的迁移,干性,耐药性和免疫抑制.
- 有证据表明,缺氧诱导因子1-alpha (HIF-1α) 介导的信号有助于这些效应.
结论:
- 根据激素受体状态,miR-18a在乳腺癌的进展中起着亚型特定的双重作用.
- 低miR-18a水平与ER阴性乳腺癌的攻击性表型有关,可能是通过HIF-1α信号传递.
- miRNA特征,特别是miR-18a,可能使ER阴性乳腺癌分层成临床相关的亚组.
相关概念视频
MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K

